The New York Times reported that the FDA was prepared to issue an emergency use authorization for the treatment last week, but NIH Director Francis Collins and NIAID Director Anthony Fauci intervened, arguing that data were too weak.
In a wide-ranging interview for BIO's virtual annual meeting with the trade and lobbying group's president, NIAID Director Anthony Fauci also said "good-faith" discussions are important to avoiding excessive pricing and ensuring affordability and access.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
It was also reported that a study sponsored by the National Institutes of Health was running ahead of schedule and could have data available in the next couple of weeks.
The randomized, placebo-controlled study of Gilead's remdesivir has been posted online and has enrolled the first patient, one of the passengers on a quarantined cruise ship docked off of Yokohama, Japan, who was repatriated to the U.S.